Search Results for: "Clinic Roundup"
-
Clinic Roundup
The safety profile of alitretinoin observed in this study was consistent with previous trials, and the new data will be integrated into regulatory submissions planned for later this yearBioWorld Today | Thursday, April 26, 2007 -
Clinic Roundup
The drug was well tolerated, with a safety profile consistent with the clinical experience of patients on dialysis using its Renagel (sevelamer hydrochloride) productBioWorld Today | Tuesday, April 17, 2007 -
Clinic Roundup
The trial is designed to determine the safety profile of Azixa and the extent of its ability to improve the overall survival of patients with melanoma skin cancer with brain metastasesBioWorld Today | Wednesday, March 28, 2007 -
Clinic Roundup
Primary objectives include determining the product's safety profile, identifying dose-limiting toxicity, finding the maximum tolerated dose and studying the pharmacokinetics, while secondary objectives will assess preliminary evidence of antitumor activityBioWorld Today | Friday, March 23, 2007 -
Clinic Roundup
Genelabs Technologies Inc., of Redwood City, Calif., said results of a clinical trial of its investigational hepatitis E virus vaccine show that it was found to be 95.5 percent effective in preventing disease caused by infection with HEV and had a safety profile similar to placebo, except for injection site painBioWorld Today | Friday, March 2, 2007 -
Clinic Roundup
Results from the trial showed that the drug was well tolerated and demonstrated an improved safety profile, which included reducing the extrapyramidal symptoms associated with available therapiesBioWorld Today | Wednesday, February 14, 2007 -
Clinic Roundup
Data from a low dose trial indicate a good safety profile and positive immune responses in human volunteers receiving a one-tenth dose of the vaccine...Results of a second larger full-dose trial also indicate a good safety profileBioWorld Today | Tuesday, February 6, 2007 -
Clinic Roundup
Ambrilia Biopharma Inc., of Montreal, said the Phase I repeat-dose study with PPL-100, the company's lead protease inhibitor to treat HIV and AIDS, demonstrated a good safety profile, and only mild adverse events were observed in the treatment groups...Ostarine continued to demonstrate a favorable safety profile, with no serious adverse events reportedBioWorld Today | Monday, December 11, 2006 -
Clinic Roundup
The key objective will be to determine the drug's efficacy in those patient populations, and secondary objectives include determining the safety profile and assessing biomarkers and predictive markers for the drugBioWorld Today | Friday, December 8, 2006 -
Clinic Roundup
Data showed that the compound has a good safety profile and established the maximum tolerated dose at 267 mg/m(2), which will be used in a Phase II trialBioWorld Today | Tuesday, November 28, 2006 -
Clinic Roundup
The compound continued to demonstrate a good safety profileBioWorld Today | Wednesday, November 22, 2006 -
Clinic Roundup
At 12 months, Orencia showed a durable response as measured by DAS28 (mean change at six months: -2.53; mean change at 12 months: -2.88), as well as a more favorable safety profile than RemicadeBioWorld Today | Thursday, November 16, 2006 -
Clinic Roundup
Inspire Pharmaceuticals Inc., of Durham, N.C., reported results of a 28-day Phase II study of denufosol inhalation solution in cystic fibrosis patients, ages 5 to 7, showing that both the 20-mg and 60-mg doses of the drug given three times daily were well tolerated, with a safety profile similar to placeboBioWorld Today | Monday, November 6, 2006 -
Clinic Roundup
LAB CGRP showed statistically significant broncho-protective effects compared to placebo and a similar safety profile to placebo except for transient and mild headaches and flushing in some of the patientsBioWorld Today | Thursday, October 5, 2006 -
Clinic Roundup
Preliminary analysis of those findings indicates that the product has a promising safety profile devoid of severe toxicityBioWorld Today | Friday, September 15, 2006 -
Clinic Roundup
It is an open-label, dose-escalation study that aims to establish the maximum tolerated dose and safety profile of PXD101BioWorld Today | Wednesday, August 9, 2006 -
Clinic Roundup
Acologix Inc., of Hayward, Calif., said results from a 40-patient Phase II feasibility study of AC-100 in periodontal defects demonstrated a favorable safety profile but the drug did not significantly regenerate more periodontal bone vsBioWorld Today | Wednesday, July 26, 2006 -
Clinic Roundup
Peplin Ltd., of Brisbane, Australia, said results from a Phase IIa trial of PEP005 topical demonstrated a favorable safety profile and showed dose-dependent tumor clearance rates in patients with nodular forms of basal-cell carcinomaBioWorld Today | Tuesday, July 18, 2006 -
Clinic Roundup
The primary objective of the Phase Ib trial is to determine the maximum tolerated dose, dose-limiting toxicity and safety profile of Reolysin when administered intratumorally to patients receiving radiationBioWorld Today | Tuesday, July 11, 2006 -
Clinic Roundup
Data showed a significant survival advantage and a favorable safety profileBioWorld Today | Wednesday, July 5, 2006
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.